Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 21, 1991 - Issue 11
Submit an article Journal homepage
15
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase

G. Muralidharan College of Pharmacy, University of Saskatchewan, Saskatoon, Saskatchewan, S7N 0W0, Canada
,
E. M. Hawes College of Pharmacy, University of Saskatchewan, Saskatoon, Saskatchewan, S7N 0W0, Canada
,
G. McKay College of Pharmacy, University of Saskatchewan, Saskatoon, Saskatchewan, S7N 0W0, Canada
&
K. K. Midha College of Pharmacy, University of Saskatchewan, Saskatoon, Saskatchewan, S7N 0W0, Canada
Pages 1441-1450 | Received 22 Aug 1990, Accepted 22 Mar 1991, Published online: 22 Sep 2008

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Shotaro Uehara, Norie Murayama, Hiroshi Yamazaki & Hiroshi Suemizu. (2019) Regioselective hydroxylation of an antiarrhythmic drug, propafenone, mediated by rat liver cytochrome P450 2D2 differs from that catalyzed by human P450 2D6. Xenobiotica 49:11, pages 1323-1331.
Read now
Susan Hurst, Cho-Ming Loi, Joanne Brodfuehrer & Ayman El-Kattan. (2007) Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opinion on Drug Metabolism & Toxicology 3:4, pages 469-489.
Read now

Articles from other publishers (11)

Tony K. L. Kiang, Kyle John Wilby & Mary H. H. Ensom. 2018. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions 515 549 .
Ayman F. El‐Kattan. 2017. Oral Bioavailability Assessment. Oral Bioavailability Assessment 35 76 .
Ayman El‐Kattan, Susan Hurst, Joanne Brodfuehrer & Cho‐Ming Loi. 2011. Oral Bioavailability. Oral Bioavailability 253 265 .
Geoffrey Edwards. 2011. Drug Interactions in Infectious Diseases. Drug Interactions in Infectious Diseases 581 611 .
Susan Hurst, Cho-Ming Loi, Joanne Brodfuehrer & Ayman El-Kattan. (2007) Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opinion on Drug Metabolism & Toxicology 3:4, pages 469-489.
Crossref
Nuggehally R. Srinivas. (2004) Simultaneous chiral analyses of multiple analytes: case studies, implications and method development considerations. Biomedical Chromatography 18:10, pages 759-784.
Crossref
Elżbieta Lorenc-Koci, Lucyna Antkiewicz-Michaluk, Jadwiga Wardas, Małgorzata Zapała & Joanna Wierońska. (2004) Effect of 1,2,3,4,-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12,935 to dopamine transporter in the rat nigrostriatal, dopaminergic system. Brain Research 1009:1-2, pages 67-81.
Crossref
Elżbieta Lorenc-Koci, Jacek Wójcikowski, Marta Kot, Anna Haduch, Jan Boksa & Władysława Anna Daniel. (2004) Disposition of 1,2,3,4,-tetrahydroisoquinoline in the brain of male Wistar and Dark Agouti rats. Brain Research 996:2, pages 168-179.
Crossref
Jennifer L. Donovan, C.Lindsay DeVane, David Boulton, Seetal Dodd & John S. Markowitz. (2003) Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo. Food and Chemical Toxicology 41:8, pages 1199-1201.
Crossref
Charles V. Vorhees, Tracy M. Reed, Mary A. Schilling, J.Edward Fisher, Mary S. Moran, Gregg D. Cappon & Daniel W. Nebert. (1998) Cyp2d1 Polymorphism in Methamphetamine-Treated Rats. Neurotoxicology and Teratology 20:3, pages 265-273.
Crossref
M.I. Colado, J.L. Williams & A.R. Green. (1995) The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. British Journal of Pharmacology 115:7, pages 1281-1289.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.